Highlights

  • RCE shares gained 7.62% to AUD 0.56 on May 27, 2026, and are up approximately 56.94% over the prior year.
  • A non-binding term sheet was signed with a leading publicly listed Middle Eastern pharmaceutical company for a 10-year exclusive licensing agreement covering R327 Topical Gel across the MENA region.
  • Commercial terms include milestone payments totalling up to USD 3.5 million, a proposed selling price of USD 1,500 per treatment, and a 30% share of net selling price plus an additional 6% annual Royalty on net sales exceeding USD 50 million per year.

 

Shares in Recce Pharmaceuticals Limited (ASX:RCE) advanced AUD 0.04 or 7.62% to AUD 0.56 on May 27, 2026, following the company's announcement of a non-binding term sheet for a 10-year exclusive licensing arrangement covering its R327 Topical Gel across the Middle East and North Africa region. The session gain extended what has been a sustained period of price appreciation for the stock, which has risen approximately 56.94% over the prior 12 months.

The trajectory of RCE's share price over the past year reflects growing investor interest in the commercial pathway for the company's anti-infective pipeline, which has progressively moved from early-stage development toward registrational Clinical Trials and now, in the case of R327 Topical Gel, a formal licensing agreement structure. The 56.94% 12-month return is notable for a clinical-stage pharmaceutical company and suggests that investors have been progressively upgrading their assessment of the probability of commercial success for the R327 platform.

 

The MENA Licensing Term Sheet: Structure and Commercial Terms

Recce signed a non-binding term sheet with a publicly listed Middle Eastern pharmaceutical company — not named in the announcement — described as one of the leading pharmaceutical companies in the MENA region, with a multi-billion-dollar Market Capitalisation and a distribution network spanning over 30 international markets. The proposed agreement covers exclusive rights for the licensee to register, market, and distribute Recce's R327 Topical Gel (R327G) for the treatment of Diabetic Foot Infections in Saudi Arabia, the six GCC countries (UAE, Kuwait, Oman, Bahrain, Qatar, and Iraq), as well as Egypt, Algeria, and Morocco.

The commercial terms of the proposed 10-year agreement are structured to deliver multiple Revenue streams to Recce. The upfront and milestone payment structure totals up to USD 3.5 million (approximately AUD 5 million). Beyond milestones, Recce is proposed to receive 30% of the net selling price per treatment — based on a proposed price of USD 1,500 per treatment — plus an additional 6% annual royalty on net sales exceeding USD 50 million per year. Recce retains responsibility for Manufacturing and Supply, which preserves its control over the production Economics of R327G.

The parties are targeting finalisation of the definitive licensing agreement during the next quarter, subject to ongoing negotiations, Due Diligence by the licensee, final documentation, and customary approvals. The term sheet is non-binding, which means there is execution risk between the current announcement and a definitive agreement — a distinction that investors in clinical-stage companies will weigh carefully.

 

The Clinical Foundation: Phase 3 Trial and Regulatory Pathway

The licensing arrangement is underpinned by Recce's ongoing Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia, which is enrolling patients toward a target of 310 DFI patients randomised between R327G and placebo. An approvable interim data readout is anticipated following enrolment of 155 patients. Subject to the outcome of the Indonesian Phase 3 trial, no additional clinical trials are expected to be required for a Marketing authorisation application in Saudi Arabia, where expedited regulatory review is anticipated for a potential commercial approval by year end.

The decision to use Indonesian Phase 3 data as the basis for a KSA regulatory submission is a meaningful efficiency in Recce's development strategy. It avoids the cost and time of a separate regional trial while leveraging the company's Investment in an already-enrolled study. The FDA has previously granted R327 Qualified Infectious Disease Product designation under the GAIN Act, providing Fast Track Designation and 10 years of market exclusivity post-approval in the US context — a designation that also contributes to the credibility of the overall development programme.

 

The MENA Diabetic Foot Infection Market

The commercial opportunity in the MENA region for R327G is anchored in the region's exceptionally high diabetes burden. With over 84 million people living with diabetes across MENA and a prevalence rate of 23.1% of the adult population in Saudi Arabia — placing it among the top ten countries globally for diabetes prevalence — the addressable patient population for treatments targeting diabetic foot infections is among the largest in the world. DFIs are a leading cause of hospitalisation, amputation, and mortality among diabetic patients, and the limitations of existing antibiotic treatments, particularly in the context of antimicrobial resistance, create a clinical and commercial gap that Recce believes R327G can address.

The World Health Organization has recognised Recce's anti-infective pipeline by listing R327 on its antibacterial products in clinical development list for priority pathogens. The WHO's endorsement, combined with the FDA's GAIN Act designation, provides institutional credibility to R327's potential as a next-generation anti-infective that addresses growing resistance concerns.

 

Broader Anti-Infective Pipeline

Beyond R327 Topical Gel, Recce's pipeline includes RECCE 327 as an intravenous therapy for serious and potentially life-threatening infections, RECCE 435 as an orally administered therapy for bacterial infections, and RECCE 529 for viral infections. All three have been added to the WHO's antibacterial products in clinical development list. The company wholly owns its automated manufacturing infrastructure, supporting both current clinical trials and the future commercial supply obligations contemplated under the MENA licensing structure.

The Pew Charitable Trusts has identified R327 as the sole synthetic polymer and sepsis drug candidate in its Global New Antibiotics in Development Pipeline — a distinction that highlights the differentiated mechanism of Recce's technology relative to conventional small-molecule antibiotic development.

 

Conclusion

Recce Pharmaceuticals' 7.62% single-session advance on May 27, 2026, against the backdrop of a 56.94% 12-month gain, reflects the market's growing confidence in the commercial pathway for R327 Topical Gel. The MENA licensing term sheet is a material step toward generating non-dilutive revenue streams from the R327 platform, with a commercial structure that includes upfront milestones, per-treatment revenue sharing, and royalties on high-Volume sales. The critical near-term milestones are the finalisation of the definitive licensing agreement targeted for next quarter, the interim data readout from the Indonesian Phase 3 trial, and the anticipated KSA regulatory submission thereafter.